Immunocore granted Genentech exclusive, worldwide rights to ImmTACs for multiple undisclosed cancer targets discovered using Immunocore's ImmTAC technology

Immunocore Ltd.

U.K. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Genentech Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced